radiation therapy

January 14, 2013 — Advanced Radiation Therapy (ART), manufacturer of the AccuBoost System for radiation therapy of partial breast and Elekta a global leader in cancer management systems and software, announced today that they have executed an agreement whereby ART acquires the assets of all AccuBoost installations held by Elekta, its worldwide distribution partner. As part of the transaction, ART has purchased the assets and the operating agreements for more than 20 installations in the U.S. The transaction is designed to enable both companies to focus on their core competencies, and serves AccuBoost user groups by allowing ART to increase its support to these installations.

Piran Sioshansi, Ph.D., President and CEO of ART, stated: "The support of Nucletron/Elekta has been helpful for the growth of the AccuBoost product to become an established treatment option for partial breast radiation therapy in the United States. With this agreement, AccuBoost will resume its lead position in support of the treatment centers and concentrate on future growth of the technology and accelerate the introduction of new treatment options."

"AccuBoost is well positioned to enter into a stage of substantial growth," Dr. Sioshansi continued, "and plans to hire additional staff and work independently with all of the providers in the radiation oncology marketplace."

Bill Dowd, Vice President, Brachytherapy, North America with Nucletron, an Elekta Company, stated: "We believe this is the best way forward for the development of AccuBoost and for customers using this solution."

The AccuBoost procedure is designed for women diagnosed with early stage breast cancer who pursue Breast Conserving Therapy (BCT). AccuBoost is a new brachytherapy modality that uses real time image guidance to target the radiation dose for patients who choose BCT. The mammography image-guided AccuBoost partial breast irradiation procedure is offered either for breast boost therapy, as part of the course of whole breast irradiation regimen or as a non-invasive monotherapy option for Accelerated Partial Breast Irradiation (APBI).

For more information: www.artcorporation.net


Related Content

News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
News | Women's Health

May 6, 2026 — GE HealthCare has announced the availability of MIM ComboTherapy GYN HDR/EBRT2, a solution designed to ...

Time May 06, 2026
arrow
News | Radiation Therapy

April 30, 2026 — The Siemens Healthineers business area, Varian, has been awarded up to $60 million over five years by ...

Time April 30, 2026
arrow
News | Breast Imaging

April 15, 2026 — QT Imaging Holdings, Inc. has launched its QTI Imaging-Olea Viewer, developed in collaboration with ...

Time April 15, 2026
arrow
News | Radiology Business

April 10, 2026 — The radiation therapy team at The Ohio State University Wexner Medical Center, The James Cancer ...

Time April 10, 2026
arrow
News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News | Breast Imaging

April 1, 2026 — QT Imaging Holdings has released its latest image reconstruction software update, version 4.5.0. This ...

Time April 02, 2026
arrow
News | Ultrasound Imaging

March 30, 2026 — Butterfly Network, Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for a ...

Time April 01, 2026
arrow
News | Breast Imaging

March 30, 2026 — Each year, the Alumni Association at the University of Missouri-Kansas City, recognizes the ...

Time March 31, 2026
arrow
News | FDA

March 20, 2026 — Siemens Healthineers recently announced its Varian TrueBeam radiotherapy systems, which include ...

Time March 24, 2026
arrow
Subscribe Now